CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to enhance early detection and treatment of ovarian and breast cancer through innovative blood tests based on DNA methylation. By improving patient stratification, it seeks to reduce late-stage diagnoses and treatment-related complications.
CLINICAL NEEDEvery year in the EU ~45,300 and 330,000 women are diagnosed with ovarian and breast cancer respectively & 28,800 and 90,000 of these two groups of women will die as a consequence of these diseases.
Currently there are no tools available that allow for:a) Effective screening of ovarian and/or breast cancer of sufficient sensitivity and specificity to avoid potential over-diagnosis, or;b) Stratification of patients into optimal personalised therapy regimes in ovarian/breast cancer.Ep…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
EUROFINS GENOMICS EUROPE PHARMA AND DIAGNOSTICS PRODUCTS & SERVICES SANGER PCR GMBH
Germany, Konstanz
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Switzerland, BASEL
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
United Kingdom, Lincoln
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Germany, MUNCHEN
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
